vaxvaxAN IAVI REPORT
BULLETIN
AIDS VACCINE TRIALS 2004:
YEAR IN REVIEWThis map depicts the clinical trials of preventive AIDS vaccines that began in 2004. For some of these trials additional sites will be added in 2005; the currentlyplanned additional sites are represented here by dashed lines. For updated information or further details about a specific trial, please visit the IAVI Vaccine TrialsDatabase (www.iavi.org/trialsdb). Please also e-mail any additions or comments to [email protected].
Abbreviations: ABL: Advanced BioScience Laboratories, Inc.; AlphaVax:AlphaVax Human Vaccines Inc.; ANRS: Agence Nationale de Recherche sur leSIDA; AVANT: AVANT Immunotherapeutics, Inc.; Aventis: Aventis Pasteur;Biovector SA: Biovector Therapeutics, SA; HVTN: HIV Vaccine Trials Network;IAVI: International AIDS Vaccine Initiative; IDT: Impfstoffwerk Dessau TornauGmbH; NIAID: US National Institute Allergy and Infectious Diseases; Therion:Therion Biologics Corporation; UMMS: University of Massachusetts MedicalSchool; VRC: Dale and Betty Bumpers Vaccine Research Center at the USNational Institutes of Health; WRAIR: Walter Reed Army Institute of Research.
MAP KEYTRIAL INFORMATION
• Month — CountriesTrial NumberPhase, No. volunteers VACCINE (CLADE)TRIAL SPONSOR; MANUFACTURER
VACCINE TYPE
DNA
Viral Vector
Protein Subunit
COLOR KEY
Dark green denotes countrieswhere trials are currently ongoing.
Light green indicates countrieswhere trials will soon begin.
• April — USAN/APhase I, 36 volunteersgag + 5 env DNA (A, B, C, E); 5 rgp120 (A, B, C, E)UMMS; ABL
• January — Thailand, Brazil, Haiti, Puerto Rico (Later: Malawi)
HVTN 050/Merck 018Phase I, 435 volunteersMRKAd5 HIV-1 gag (B)NIAID; MERCK
• February — FinlandC060301Phase I/II, 28 volunteersGTU-MultiHIV (B)FIT BIOTECH
• April — USAHVTN 056Phase I, 96 volunteersHIV CTL MEP (B)NIAID; WYETH
• May — USAN/APhase I, 18 volunteersLFn-p24 (B)NIAID, WRAIR; AVANT
• May — USAVRC 006 (04-I-0172)Phase I, 36 volunteersVRC-HIVADV014-00-VP (B); VRC-HIVADV014-00-VP (A, B, C)NIAID; GENVEC
• June — USAHVTN 042/ANRS VAC 19Phase I/II, 174 volunteersLIPO-5 (B); ALVAC-HIV (vCP1452) (B)HVTN, ANRS; AVENTIS
• July — FranceANRS VAC 16Phase I, 70 volunteersLIPO-4T (B)ANRS; BIOVECTOR SA
• July — USAHVTN 055Phase I, 150 volunteersTBC-M358 (MVA) (B); TBC-M335 (MVA) (B); TBC-F357 (FPV) (B); TBC-F349 (FPV) (B)NIAID; THERION
• August — USAVRC 007 (04-I-0254)Phase I, 15 volunteersVRC-HIVDNA016-00-VP (A, B, C)NIAID/VRC; VICAL
• September — FranceANRS VAC 18Phase II, 132 volunteersLIPO-5 (B)ANRS; AVENTIS
• October — USAHVTN 059Phase I, 96 volunteersAVX101 (VEE) gag (C)NIAID; ALPHAVAX
• November — USAHVTN 057 (rollover from HVTN 052)Phase I, 70 volunteersVRC-HIVADV014-00-VP (A,B,C)NIAID/VRC; VICAL
• December — USA (Later: Peru, Dominican Republic, Haiti, Puerto Rico, Australia, Canada)
HVTN 502/Merck023Phase IIb, 1500 volunteersMRKAd5 HIV-1 gag/pol/nef (B)HVTN, MERCK; MERCK
• January 2005 — USAIAVI C002Phase I, 48 volunteersADMVA (C)IAVI; IDT
Recommended
